METHODS AND COMPOSITIONS FOR LOCATING SNP HETEROZYGOSITY FOR ALLELE SPECIFIC DIAGNOSIS AND THERAPY

• US 20100151470A1
• Filed: 10/30/2009
• Published: 06/17/2010
• Est. Priority Date: 05/01/2007
• Status: Abandoned Application

• Current Assignee: University Of Massachusetts
• Original Assignee: University Of Massachusetts
• Inventors: ZAMORE, PHILLIP D., ARONIN, NEIL
• Application Number:
  US12/609,474
• Publication Number:
  US 20100151470A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers

Abstract

The present invention provides methods for the rapid and cost effective identification of the presence of a disease-associated mutation and a particular SNP in the same allele of a gene without the need to clone and sequence the entire gene. The compositions and methods of the invention are useful for identification of patient to subpopulations amenable to treatment as part of a therapeutic strategy for treating genetic disorders, for example, dominant, gain-of-function gene mutations, for example, Huntington'"'"'s Disease (HD).

Claims

1. A method for identifying the association between a disease-associated mutation and single nucleotide polymorphism (SNP) within a nucleic acid region comprising,

obtaining a linear derivative of the nucleic acid region wherein the region comprises at least one SNP associated with the region,

connecting the ends of the linear derivative to form a circular species in which the disease-associated mutation and SNP are positioned in closer proximity than the naturally-occurring disease associated mutation and SNP,

producing at least a portion of the circular species containing the disease-associated mutation and SNP and,

detecting the presence of the SNP and disease associated mutation thereby identifying their association within the same nucleic acid region.

3. The method of claim 1 or 2, wherein the identified SNP association is suitable for targeting using gene silencing for achieving therapy for the disease associated mutation.

4. The method of claim 1, wherein the nucleic acid region is DNA or RNA

5. The method of claim 1, wherein the nucleic acid region is a cDNA region, genomic region, chromosomal region, or fragment thereof.

6. The method of claim 1, wherein the obtaining of the linear derivative of the nucleic acid region is by PCR or RT-PCR amplification.

7. The method of claim 1, wherein the obtaining of the linear derivative of the nucleic acid region is obtained by chemical, physical, or enzymatic cleavage of the nucleic acid region.

8. The method of claim 1 or 2, wherein the connecting of the ends of the circular species is by enzymatic ligation.

9. The method of claim 1 or 2, wherein the producing of a portion of the circular species to is achieved by PCR or RT-PCR.

10. The method of claim 1 or 2, wherein the detecting of the presence of the SNP nucleotide is achieved by nucleic acid sequencing.

11. The method of claim 1 or 2, wherein the detecting of the presence of the SNP nucleotide is achieved by nucleic acid hybridization or chip based affinity hybridization.

12. The method of claim 1 or 2, wherein the contacting with a RISC complex is performed in vitro using a cellular extract from Drosophila.

16. The method of claim 1 or 2, wherein said disease-associated mutation is a dominant, gain-of-function mutation.

17. The method of claim 1 or 2, wherein said disease-associated mutation is an oncogenic mutation.

18. The method of claim 1 or 2, wherein said disease-associated mutation comprises an expanded trinucleotide repeat region.

19. The method of claim 1 or 2, wherein disease-associated mutation causes a disease selected from the group consisting of Huntington'"'"'s disease, spino-cerebellar ataxia type 1, spino-cerebellar ataxia type 2, spino-cerebellar ataxia type 3, spino-cerebellar ataxia type 6, spino-cerebellar ataxia type 7, spino-cerebellar ataxia type 8, spino-cerebellar ataxia type 12, fragile X syndrome, fragile XE MR, Friedreich ataxia, myotonic to dystrophy, spinal bulbar muscular disease and dentatoiubral-pallidoluysian atrophy.

20. The method of claim 1 or 2, wherein the disease is Huntington'"'"'s disease.

21. The method of any of the above claims for diagnosing a subject having or at risk for a disease arising from a disease-associated mutation.

22. The method of claim 3, wherein therapy is achieved by specifically targeting the disease-associated mutation of an allelic polymorphism encoding a mutant protein.

23. The method of claim 22, wherein the cognate wild type allele of the allelic polymorphism encoding a wild type protein is correctly expressed.

27. A method for identifying a patient or patient subpopulation amenable to SNP-targeted RNAi therapy wherein the patient or patient subpopulation is first identified as in need of such therapy according to the methods of any one of the preceding claims.

2. A method for identifying the association between a disease-associated mutation and SNP nucleotide in an RNA molecule comprising,

contacting the RNA molecule with a RISC complex programmed with a gene silencing agent for the SNP, wherein SNP-specific RNA cleavage is achieved,

connecting the ends of the fragments of cleaved RNA to form a circular species,

producing a portion of the circularized species containing the disease-associated mutation and,

detecting the presence of the SNP and disease-associated mutation thereby identifying their association in the same RNA molecule.

13. The method of claim 2, wherein the RNA is mRNA

14. The method of claim 2, wherein RNA is obtained by reverse transcription from DNA

15. The method of claim 2, wherein producing said portion of said circularized RNA is achieved by RT-PCR

24. A kit for carrying out the methods of any one of the above preceding claims.

25. The kit of claim 24, wherein the kit comprises SNP sequence information or SNP nucleic acid suitable for targeting a disease associated mutation and instructions for use.

26. Use of SNP information or SNP nucleic acid sequence as disclosed herein or as identified according to any of the preceding methods for use in a kit, pharmaceutical composition, research, diagnosis, or therapy.